ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0978

IL-17A+ HLA-DR-CCR6+ regulatory T cells: Dual role in T cell suppression and synovial inflammation in arthritis.

Bennie Heeswijk1, Margot Bongenaar1, Nadine Davelaar1, Pascal de Jong1, Hannah den Braanker1, Radboud Dolhain1 and Erik Lubberts2, 1Erasmus University Medical Center, Rotterdam, the Netherlands, Rotterdam, Netherlands, 2Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands

Meeting: ACR Convergence 2025

Keywords: Fibroblasts, Synovial, rheumatoid arthritis, TH17 Cells, Treg cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (0978–1006) T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Regulatory T cells (Tregs) are essential for maintaining immune tolerance and limiting excessive immune responses. However, Tregs show high levels of heterogeneity and plasticity, indicated by the production of IL-17A. In rheumatoid arthritis (RA), IL-17A intensifies synovial inflammation by activating synovial fibroblasts. We aim to characterize Treg heterogeneity in RA patients and examine their functional characteristics and role in synovial inflammation.

Methods: CITE-seq was applied to T cells from four treatment-naïve RA patients and four healthy controls. Unsupervised clustering was performed to identify Treg subpopulations. These subpopulations were verified in PBMCs from 150 RA patients and 30 healthy controls using flow cytometry. A suppression assay was conducted to evaluate the suppressive capacity of the sorted Treg subpopulations. In addition, the cytokine-secreting potential of sorted Treg subpopulations was investigated using ELISA, as well as the effect of interaction with RA synovial fibroblasts on cytokine secretion.

Results: CITE-seq analysis from treatment-naïve early RA patients identified Treg subpopulations based on the presence of HLA-DR and CCR6. We verified the surface expression of HLA-DR and CCR6 on Tregs in PBMCs of patients with established RA, revealing a significant decrease in HLA-DR-CCR6+ Treg cells in RA patients compared to healthy individuals. Significantly fewer HLA-DR-CCR6+ Tregs were detected specifically in RA patients with moderate and severe disease activity. We analysed suppressive function, cytokine secretion, and fibroblast interaction to investigate the functional differences between these subpopulations. We found that all Treg subpopulations suppress proliferation of CD4+ responder cells. In addition, we revealed that activated HLA-DR-CCR6+ Treg exclusively secreted IL-17A. Co-cultures with RA synovial fibroblasts showed that HLA-DR-CCR6+ Tregs induced synovial fibroblast activation, indicated by the secretion of IL-6, IL-8, and MMP-3. Interestingly, IL-17A secretion was increased upon coculturing HLA-DR-CCR6+ Treg and synovial fibroblast , highlighting the potential plasticity of this HLA-DR-CCR6+ Treg subpopulation towards a proinflammatory phenotype.

Conclusion: Regulatory T cell subsets defined by HLA-DR and CCR6 markers were identified across different stages of RA and exhibited notable functional heterogeneity. Despite maintaining suppressive capacity, some subsets, particularly HLA-DR⁻CCR6⁺ Tregs, displayed pro-inflammatory features, including IL-17A secretion and activation of synovial fibroblasts. These findings underscore the complexity of Treg biology in RA and suggest that HLA-DR⁻CCR6⁺ Tregs may paradoxically contribute to disease progression under inflammatory conditions.

Supporting image 1Schematic overview of Treg subpopulation characteristics


Disclosures: B. Heeswijk: None; M. Bongenaar: None; N. Davelaar: None; P. de Jong: AbbVie/Abbott, 1, 5, 6, Eli Lilly, 5; H. den Braanker: None; R. Dolhain: Abbvie, 6, AstraZeneca, 6, Eli Lilly, 6, Galapagos, 5, Genzyme, 6, Novartis, 6, Roche, 6, UCB, 5, 6; E. Lubberts: None.

To cite this abstract in AMA style:

Heeswijk B, Bongenaar M, Davelaar N, de Jong P, den Braanker H, Dolhain R, Lubberts E. IL-17A+ HLA-DR-CCR6+ regulatory T cells: Dual role in T cell suppression and synovial inflammation in arthritis. [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/il-17a-hla-dr-ccr6-regulatory-t-cells-dual-role-in-t-cell-suppression-and-synovial-inflammation-in-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/il-17a-hla-dr-ccr6-regulatory-t-cells-dual-role-in-t-cell-suppression-and-synovial-inflammation-in-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology